Clinical trials: Paclitaxel, completed
Carcinoma, Fallopian Tube Cancer
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube…
- Conditions
- Carcinoma, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01253681
- Testing
- AMG 386, paclitaxel and carboplatin
- Where
- 8 sites in Australia, Belgium and 1 more
- Volunteers
- 27 people
- Sponsor
- Amgen
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer, Fallopian Tube Cancer
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
This study will look at the efficacy and safety of weekly administration of paclitaxel (Taxol®) in monotherapy compared to paclitaxel in combination with topotecan or carboplatin in patients with ovarian cancer in early relapse.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Malignant Tumor of Peritoneum
- Trial name
- NCT00189566
- Testing
- Paclitaxel, Topotecan, Carboplatin
- Where
- France
- Volunteers
- 165 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer (OvCa), Fallopian Tube Cancers
Taste Alteration, Sarcopenia, and Malnutrition in Gynecologic Cancer Patients Receiving Carboplatin-Paclitaxel Chemotherapy
This observational study aims to evaluate chemotherapy-induced taste alterations, sarcopenia, and malnutrition in patients with gynecologic malignancies (ovarian, fallopian tube, and endometrial cancer) treated with standard…
- Conditions
- Ovarian Cancer (OvCa), Fallopian Tube Cancers, Endometrial Cancer, Chemotherapy-Induced Taste Alteration
- Trial name
- GYM-TASTE (NCT07154966)
- Testing
- Standard Chemotherapy (Carboplatin-Paclitaxel)
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people
- Sponsor
- Ankara Etlik City Hospital
Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma
Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer
GastroPET is a prospective, multicenter, non-randomized interventional study evaluating sequential FDG-PET as an early biomarker to guide preoperative treatment in patients with locally advanced resectable oesophago-gastric…
- Conditions
- Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GastroPET (NCT07791329)
- Testing
- FDG-PET
- Where
- Czechia
- Volunteers
- 144 people
- Sponsor
- Masaryk Memorial Cancer Institute
Breast Cancer
Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer
The study is a prospective randomized control clinical trial which is sponsored by the researchers. The purpose of this study is to determine the effectiveness of Gonadotropin-Releasing hormone agonist on ovarian function for…
- Trial name
- POF (NCT02483767)
- Testing
- goserelin, standard chemotherapy
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
Carcinoma, Non-Small-Cell Lung
Pulsed Paclitaxel And Daily Thoracic Radiotherapy For Inoperable (Stage I/II) Or Unresectable Lung Cancer
A treatment study is being conducted by the University of Rochester Cancer Center (URCC) in which patients with non-small cell lung cancer will be treated with radiation therapy and a drug called paclitaxel.
- Trial name
- NCT00178256
- Testing
- Paclitaxel, Radiation Therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Rochester
Breast Cancer
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
The aim of this international open-label randomized phase II trial is to evaluate the efficacy and safety of an all-oral combination and two all-intravenous combinations as first-line therapy for HER2-negative mBC patients.
- Trial name
- NCT03887130
- Testing
- oral vinorelbine, Capecitabine, Gemcitabine 1250 mg/m²
- Volunteers
- 152 people
- Sponsor
- Pierre Fabre Medicament
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or…
- Trial name
- NCT02514551
- Testing
- Ramucirumab, Paclitaxel
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors
This is a Phase 1 open-label study and consists of 3 treatment groups (dose levels) . Treatment cycles are 3 weeks in duration. The primary objective of this study is to determine the recommended phase two dose (RPTD) of…
- Trial name
- NCT01617928
- Testing
- veliparib (ABT-888), carboplatin, paclitaxel
- Where
- Japan
- Volunteers
- 12 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Metastatic Breast Cancer
Non-interventional Study With Nab-Paclitaxel (Abraxane®)
The purpose of this non-interventional study is to collect data on the efficacy and safety of Nab-Paclitaxel in the routine application.
- Trial name
- NABUCCO (NCT01689610)
- Where
- Germany
- Volunteers
- 705 people
- Sponsor
- iOMEDICO AG
Lung Cancer
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00795340
- Testing
- carboplatin, cediranib maleate, paclitaxel
- Where
- 19 sites in Brazil, Canada
- Volunteers
- 306 people
- Sponsor
- NCIC Clinical Trials Group
Ovarian Neoplasms
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
This is a Phase 2 randomized study with two treatment arms to compare the effectiveness of oregovomab (a murine monoclonal antibody directed against cancer antigen 125 (CA125)) when combined with first-line chemotherapy…
- Trial name
- NCT01616303
- Testing
- Carboplatin, Paclitaxel, oregovomab
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- Quest PharmaTech Inc.
Sarcoma
Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with AIDS-related…
- Trial name
- NCT00003008
- Testing
- indinavir sulfate, nelfinavir mesylate, paclitaxel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Eastern Cooperative Oncology Group
Unspecified Adult Solid Tumor, Protocol Specific
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005078
- Testing
- carboplatin, paclitaxel, tirapazamine
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Cancer
Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel
The aim of the study is to determine the MTD of Paclitaxel in association with metronomic Cyclophosphamide.
- Trial name
- PAL-ANGI2 (NCT01374620)
- Testing
- Paclitaxel dose escalation, Paclitaxel, Cyclophosphamide
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Oscar Lambret
Carcinoma, Non-Small-Cell Lung
Afatinib in NSCLC With HER2 Mutation
to investigate effectiveness and safety of afatinib in the advanced NSCLC patients with HER2 mutations, previously treated with 1 or 2 chemotherapy regimens
- Trial name
- NCT02597946
- Testing
- afatinib, paclitaxel
- Where
- 9 sites in China, Malaysia
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Metastatic Pancreatic Cancer
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
This is an open-label, single arm, multi-center, Phase II trial to evaluate the progression free survival in patients with metastatic adenocarcinoma of the pancreas treated with a hedgehog inhibitor (GDC-0449) in combination with…
- Trial name
- NCT01088815
- Testing
- Gemcitabine, nab-Paclitaxel, GDC-0449
- Where
- 3 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Cancer, Stage IV Pancreatic Cancer
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
- Trial name
- NCT02005315
- Testing
- Vantictumab, Nab-Paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Breast Cancer
Relationship of pAKT to Survival in Patients With Node-Positive Breast Cancer
This study will examine the relationship of a protein called pAKT to survival of breast cancer patients with one or more positive axillary lymph nodes.
- Trial name
- NCT00965276
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.